Johnson & Johnson vs Sarepta Therapeutics, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
4.4
Bearish
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
SRPT
Healthy balance sheet and financial position.
⚠ currently unprofitable (-32% margin).
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
HOLD
Target $21.78 (+1.4%)
23 analysts
Fundamentals
JNJ
SRPT
26.3×
Trailing P/E
—
17.9×
Forward P/E
7.2×
21.8%
Profit Margin
-32.5%
68.0%
Gross Margin
-7.4%
26.4%
ROE
-53.5%
9.9%
Revenue Growth
-32.7%
-52.9%
Earnings Growth
—
0.33
Beta
0.28
—
Price / Book
—
$546.9B
Market Cap
$2.3B
$146 – $252
52-Week Range
$10 – $65
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →